A clinical study published in Medicine found that Prolanza, a sustained-release ashwagandha extract manufactured by Nutriventia, reduced self-reported and physiological markers of stress in healthy adults when taken at both 150 mg and 300 mg daily.

“Building on our commitment to delivering scientifically validated, consumer-friendly nutraceuticals, this study demonstrates that even a low daily dose of Prolanza can significantly reduce perceived stress, while also improving sleep quality, feelings of happiness, and eating behaviors. This sustained-release formulation offers a convenient once-daily regimen, supporting better compliance without compromising efficacy,” said Rajat Mittal Shah, co-founder of Nutriventia.

Key Details

135 healthy adults between the ages of 20 and 55 who reported moderate stress at baseline (Perceived Stress Scale scores between 14 and 26) participated in the study. They were randomized to receive either a 150 mg or 300 mg dose of Prolanza, or a placebo, for 60 days.

Primary outcomes included Perceived Stress Scale (PSS), Pittsburgh Sleep Quality Index (PSQI), Oxford Happiness Questionnaire-8, Three-Factor Eating Questionnaire, and serum cortisol levels.

Key findings included:

• Significant stress reduction, with 150 mg and 300 mg doses of Prolanza associated with PSS score reductions of 38.6% and 41.6%, respectively, compared to placebo.
• Significant improvements in PSQI and Oxford Happiness Questionnaire scores, measuring self-assessments of sleep quality and happiness.
• Significant improvements in the Three-Factor Eating Questionnaire scores in both groups compared to placebo, indicating that treatment groups perceived improvements in their eating behavior.
• Lower cortisol levels, with significant serum cortisol reductions observed in the 300 mg group by day 60 (p<0.05).

Both doses were well-tolerated, with no safety concerns reported.

“Along with revalidating the beneficial effects of Prolanza 300 mg in reducing stress and improving sleep and psychological well-being, this study has additionally demonstrated benefits of Prolanza 300 mg in reducing stress-related eating,” said Shefali Thanawala, BAMS, assistant vice president of medical sciences and research. “Importantly, improvements were observed across all these parameters even with the 150 mg of Prolanza. Thus, this study is instrumental in strengthening the scientific evidence for effective use of both doses of Prolanza, while maintaining consumer-friendly convenience and compliance with just one-a-day doses.”